Skip to main
  1. Stocks
  2. Janux Therapeutics
  3. Forecast
JANX

Janux Therapeutics (JANX) Stock Forecast & Price Target

Janux Therapeutics (JANX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 31%
Hold 15%
Sell 8%
Strong Sell 0%

Bulls say

Janux Therapeutics is supported by a differentiated tumor-activated masking platform that may solve the core historical limitation of T cell engagers by improving safety while preserving efficacy, with JANX007 emerging as a potentially viable PSMA therapy in mCRPC. The investment case is strengthened by multiple near-term catalysts, including continued enrollment in taxane-naive mCRPC and a key JANX007 update in 1H27, which could show durability competitive with the ~11.5-12m rPFS benchmark set by Pluvicto in PSMAfore. Financially, the company ended 2Q26 with $971m in cash and is viewed as well capitalized, while broader optionality from JANX013, JANX014, and JANX011 plus multiple pharma partnerships could support rerating.

Bears say

Janux Therapeutics is a clinical-stage biopharmaceutical company facing a materially risky path because its outlook hinges on JANX007 delivering both strong efficacy and acceptable safety, while any disappointment in the program could severely undermine the investment case. The company also faces meaningful execution risk from potential delays in R&D, regulatory, or commercial development, alongside intensifying competition in the mCRPC space that could limit future adoption and strategic flexibility. In addition, the need to secure sufficient capital for research, combined with product, supply chain, liquidity, partnership, legal, intellectual property, macroeconomic, and geopolitical risks, creates a highly uncertain fundamental profile.

Janux Therapeutics (JANX) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 31% recommend Buy, 15% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Janux Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Janux Therapeutics (JANX) Analyst Forecast & Price Prediction

Get the latest Janux Therapeutics (JANX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Janux Therapeutics (JANX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Janux Therapeutics (JANX) Forecast

Analysts have given Janux Therapeutics (JANX) a Buy based on their latest research and market trends.

According to 13 analysts, Janux Therapeutics (JANX) has a Buy consensus rating as of Oct 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Janux Therapeutics (JANX)


Janux Therapeutics (JANX) Analyst Forecast & Price Prediction

Get the latest Janux Therapeutics (JANX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Janux Therapeutics (JANX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover JANX stock data and trends